FDA Panel to Rule on Wellness Peptides From Compounding Pharmacies

A panel of FDA advisers will meet this week to decide whether specialised compounding pharmacies should be permitted to produce popular wellness peptides. The substances have surged in popularity as health and recovery supplements in recent years. The panel's recommendations could significantly affect both the pharmaceutical industry and consumers who rely on these products.